Bausch Health Q3 2023 Earnings Report
Key Takeaways
Bausch Health announced its third-quarter 2023 financial results, with revenue of $2.24 billion, up 9% on both a Reported and Organic basis. All segments showed year-over-year revenue growth. The company's Adjusted EBITDA was $830 Million, up 8%. They also received FDA approval for CABTREOTM and provided updated full-year Revenue and Adjusted EBITDA guidance.
Revenue of $2.24 billion, up 9% on both a Reported and Organic basis
Year-over-year revenue growth in all segments on both a Reported and Organic Basis
Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) of $830 Million, up 8%
Received U.S. Food and Drug Administration ( FDA ) approval for CABTREOTM (IDP-126)
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Forward Guidance
The Company updated its full-year revenue and Adjusted EBITDA guidance:
Revenue & Expenses
Visualization of income flow from segment revenue to net income